Evidence map›Paper›PMID 42120702›Full record

ArticleMikrochimica acta2026

Serum KIM-1 molecular early warning radar: SERS combined with artificial intelligence for accurate early diagnosis of chronic kidney disease.

Zengshan Yu, Yanjun Wu, Shan Guo, Zelong Li, Jiahao Cui, Guochao Shi

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zengshan Yu *Hebei Key Laboratory of Nerve Injury and Repair, Chengde Medical University, Chengde, Hebei, 067000, China.
Yanjun Wu *Hebei International Research Center for Medical-Engineering, Chengde Medical University, Chengde, Hebei, 067000, China.
Shan GuoHebei Key Laboratory of Nerve Injury and Repair, Chengde Medical University, Chengde, Hebei, 067000, China.
Zelong LiHebei Key Laboratory of Nerve Injury and Repair, Chengde Medical University, Chengde, Hebei, 067000, China.
Jiahao CuiHebei Key Laboratory of Nerve Injury and Repair, Chengde Medical University, Chengde, Hebei, 067000, China.
Guochao ShiHebei Key Laboratory of Nerve Injury and Repair, Chengde Medical University, Chengde, Hebei, 067000, China. sgc@cdmc.edu.cn.

Funding

Science Research Project of Hebei Education Department BJ2025135
6 · The paper itself

Abstract

Chronic kidney disease (CKD) has become a major global public health issue. Due to its insidious onset and atypical early symptoms, patients often fail to detect it in time and receive effective intervention. Therefore, conducting early screening and diagnosis is of great significance for delaying the progression of renal failure and reducing the burden on patients and society. Combining surface-enhanced Raman scattering (SERS) technology, immunochromatography and artificial intelligence algorithm, this study utilized serum kidney injury molecule-1 (KIM-1) molecule as a key biomarker to construct a serum-based CKD diagnostic model, aiming to achieve efficient and accurate CKD screening. A total of six models were included for comparative analysis, among which the extreme gradient boosting (XGBoost) model successfully achieved precise classification of CKD, with a classification accuracy of 98.42% and an area under the curve (AUC) of 99.96%. Furthermore, leave-one-out cross-validation was used to validate this model, with an overall classification accuracy of 96.79%. These results indicated that the model exhibited good stability and strong robustness. In conclusion, the artificial intelligence-driven immunochromatography SERS biosensing technology with serum KIM-1 molecule as the early warning radar is expected to become a new technical strategy for intelligent early screening and auxiliary diagnosis of CKD.

Indexed as

Artificial IntelligenceHepatitis A Virus Cellular Receptor 1Renal Insufficiency, ChronicSpectrum Analysis, RamanBiomarkersChromatography, AffinityEarly DiagnosisGoldHumansBiomarkersGoldHAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1Artificial IntelligenceBiosensingCKDImmunochromatographySERS

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.